Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization

Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization - Intravitreal tPA and ranibizumab for type 2 choroidal neovascularization

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016870

Enrollment

Registered

2015-03-23

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subfoveal type 2 choroidal neovascularization

Interventions

intravitreal tissue plasminogen activator + ranibizumab intravitreal ranibizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: eyes diagnosed as subfoveal type 2 CNV associated with AMD without massive subretinal hemorrhage over 1 disc diameter and with baseline best-corrected visual acuity (BCVA) between 20/200 and 20/40

Exclusion criteria

Exclusion criteria: eyes with previous photodynamic therapy, medication for glaucoma, diabetic retinopathy, epiretinal membrane, vitreomacular traction, or high myopia (-6.0 diopters or worse)

Design outcomes

Primary

Measure	Time frame
Best-ocrrected visual acuity	—

Secondary

Measure	Time frame
central retinal thickness and macular volume on optical coherence tomography	—

Countries

Japan

Contacts

Public ContactTsutomu Yasukawa

Nagoya City University Graduate School of Medical Sciences Ophthalmology and Visual Science

yasukawa@med.nagoya-cu.ac.jp+81-52-8538251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026